Cialis ist bekannt für seine lange Wirkdauer von bis zu 36 Stunden. Dadurch unterscheidet es sich deutlich von Viagra. Viele Schweizer vergleichen daher Preise und schauen nach Angeboten unter dem Begriff cialis generika schweiz, da Generika erschwinglicher sind.
Public, products and employers liability
Level 3, 31 Ventnor Ave West Perth 
PO Box 1141 West Perth WA 6872 AUS (08) 9420 7900 
New Business Questionnaire 
INT +61 8 9420 7900 W 
edgeunderwriting.com.au 
PUBLIC LIABILITY 
PRODUCTS LIABILITY
 
 IMPORTANT NOTICES 
For your protection under legislation, we are required to inform you of your duty of disclosure and draw your attention to the following 
important information. 
DUTY OF DISCLOSURE 
The Insurance Contracts Act 1984 requires insurance companies to provide certain information to people intending to insure with them. The 
information concerns the duty of disclosure of an intending Insured and the effect of particular types of clauses in a proposed insurance policy. 
Where an Insurance Broker is involved in the transaction, the information is to be provided by the broker. The Insurance (Agents and Brokers) 
Act 1984 also requires us to inform you about some other matters where they are relevant to particular policies. 
 
WHAT INFORMATION DOES AN INSURANCE COMPANY/BROKER HAVE TO GIVE YOU? 
In general terms, the kind of information which an insurance company/broker must give you is as follows: 
 
YOUR DUTY OF DISCLOSURE – CONTRACTS OF GENERAL INSURANCE SUBJECT TO INSURANCE CONTRACTS ACT 
Before you enter into a contract of general insurance with an Insurer, you have a duty, under the Insurance Contracts Act 1984, to 
disclose to the Insurer every matter that you know, or could reasonably be expected to know, that is relevant to the Insurer's decision whether to 
accept the risk of the insurance, and if so on what terms. 
You have the same duty to disclose those matters to the Insurer before you renew, extend, vary or reinstate a contract of general insurance. 
Your duty, however, does not require disclosure of matter: 
 
that diminishes the risk to be undertaken by the Insurer, 
that is of common knowledge, 
that your Insurer knows or, in the ordinary course of his business, ought to know, 
as to which compliance with your duty is waived by the Insurer. 
 
NON-DISCLOSURE 
If you fail to comply with your duty of disclosure, the Insurer may be entitled to reduce their liability under the contract in respect of a claim or may 
cancel the contract. 
If your non-disclosure is fraudulent, the Insurer may also have the option of avoiding the contract from its beginning. 
 
CLAIMS MADE INSURANCE 
Your attention is drawn to the fact that if the Errors & Omissions section of this policy is selected, the cover will be placed on a "claims made" 
basis which means that claims first advised to you (or made against you) and reported to your insurer during the Period of Insurance are 
recoverable irrespective of when the incident causing the claim occurred, subject to the provisions of any clause relating to a "retroactive date". 
You should also note that, in terms of the provisions of Section 40(3) of the Insurance Contracts Act 1984, where you give notice in writing to the 
Insurer of facts that might give rise to a claim against you as soon as is reasonably practicable after you become aware of those facts (but before 
the insurance cover provided by the contract expires) then the Insurer is not relieved of liability under the contract in respect of the claim, when 
made, by reason only that it was made after the expiration of the Period of Insurance cover provided by the contract. 
Please note that your duty applies also when you seek to renew, extend, alter or reinstate a policy. 
      
QUESTIONS 
Full Name (s) of all companies to be included: 
Address of Registered Office: Address(es) of any Overseas Offices to be Insured: Full Business Description: Website Address: When established: Is your company involved in Clinical Trials? 
If ‘YES' then please contact us for specific proposal form 
PLEASE ATTACH PRODUCT BROCHURES AND ADDITIONAL COMPANY INFORMATION AS 
PUBLIC AND PRODUCTS LIABILITY 
Please complete all below 
Estimated annual turnover split between: 
i) Own Manufacture (where you hold the 
Product Licence) 
ii) Where you hold the Product Licence but 
manufacture is contracted to third party 
iii) Where you Contract Manufacture for third 
iv) Wholesale (unaltered from manufacturers) 
v) Parallel Import / Repackaged or relabelled 
Wholesale Products 
* Please provide full details of how income is generated (if appropriate please provide specimen 
contracts): 
 
      
 Please list your three largest selling products / are they Own Manufacture / date first supplied : 1. 
Please state estimated 
ii) Product 
iii) Contract 
vi) Other 
annual turnover to: 
Manufacture 
Manufacture 
Wholesale 
Are any exports sent direct to customer from 
manufacturers outside Australia 
 
If ‘YES' please advise territory sent from: 
Is there a formal contract in place regarding Quality 
Control?: 
USA/CANADA 
Please answer this question ONLY if you export to 
A full description of all products exported 
How long have you been producing each 
Do you comply with the State/Federal Laws 
applicable to each product? 
Do you have any Power of Attorney or assets 
in the USA/Canada? If ‘YES' do they arrange separate insurance including Completed Operations/Products 
      
Are you required to Indemnify any Vendors 
and/or Distributors in USA/Canada If ‘YES' please provide names and addresses If ‘NO' do they maintain their own insurance for Completed Operations/Products? State limit if known 
If you import products please state from which 
countries obtained and approximately percentage of total turnover against each. 
PRODUCTS 
Do products comply with all relevant:- 
a) Australian Standard, Industry and Trade 
Standards or Government Safety Licensing Regulations or equivalent local legislation. 
b) Official Standard or Government Regulations 
laid down in countries to which Products are exported? 
Are any new products likely to be marketed during 
the next 12 months. If ‘YES' please advise product name and product type 
a) Please give full details and percentage of total 
turnover of products that are: 
manufactured/supplied to own 
manufactured/supplied to a 
design/specification/formulation laid down by a customer 
b) Do you have a separate design team? 
Describe extent and type of tests and checks 
undertaken before Product goes into production. 
      
QUALITY CONTROL 
a) Do you have a written policy relating to Quality 
How often is it reviewed? 
b) Do you have a specific Quality Control Team? 
(i) who has overall responsibility? 
(ii) can control be overridden by Design 
Production or Marketing Personnel? 
c) Does Quality Control involve the testing of a 
sample percentage of product? 
If Yes, please state: 
a) percentage of products checked 
b) Failure rate. 
d) Are sampling inspections made on incoming 
e) What is the procedure for dealing with 
customers complaints? 
Are records of complaints retained? 
 If ‘YES' for how long 
a) Is it possible to trace the ultimate customer of 
individual products or batches in order to recall the products? 
b) Is there an formal procedure for emergency 
c) Has recall every been necessary or been 
considered? If YES, please give details 
d) Please give details of Product lines 
discontinued because of incidence or injury or damage, or where potential hazards have been identified – stating when manufacture or supply ceased 
      
MARKETING 
a) Are products labelled and supplied with clear 
instructions in the language of the country to which they are supplied? 
b) Are products hazard warnings clearly shown on 
Products, Packaging and/or Instruction Manuals? 
c) Do your Legal and/or Design Departments have 
sight of all advertising material, sales brochures, operating manuals etc. To check for misleading statements? 
d) Are your Representatives warned against 
overstating usage or effectiveness of Products? 
a) Do you maintain an adequate system of 
records which would enable identification of:- (please indicate period records are kept for) 
source of Product/raw 
materials/component parts purchased? 
source of design of Products 
Quality control and testing procedures 
effective at the time of design and/or manufacture? 
Research undertaken to minimise risk to 
health and safety. 
      
SPECIFIED PRODUCTS 
UNLESS IT IS SPECIFICALLY AGREED WITH UNDERWRITERS COVER PROVIDED MAY 
EXCLUDE ANY LIABILITY ARISING OUT OF THE FOLLOWING. 
Agent Orange – 
Dichlorophenoxyacetic Acid (2,4-D) and Trichlorophenoxyacetic Acid (2,4, 5-T) Alosetrin 
Methyl Tertiary Butyl Ether 
Any product that does not have 
regulatory approval Apomorphine 
Blood Borne Pathogens 
Blood/Plasma Products 
Pertussis Vaccine 
Bromfenac Sodium 
Phenylpropanolamine (PPA) 
Primodos/Amenorone Forte 
Rapacuronium Bromide 
(i) the concomitant or combined use of two or more different products which contain a) a Statin and b) a Fibrate (ii) Rhabdomyolysis arising out of either of the above Chromated Copper Arsenate 
RotaShield Vaccine 
Contraceptives (including birth 
Selective Seritonin Reuptake 
control pills) fertility drugs and 
products specifically designed and marketed for use during and in connection with pregnancy Cox – 2 Inhibitors 
Dexfenfluramine Fenfluramine or 
Silicone – any product 
containing silicone which is in any form implanted or injected in the body 
Dicyclomine when give to children 
Skin whitening and lightening 
under 4 years of age 
Diethylstilbestrol or Stilbestrol or 
      
Swine-Flu Vaccine 
Ephedrine Ma Huang 
Pseudoephedrin Chinese Ephedra Mahuang Extract Ephedra Ephedra Sinica Ephedra Extract Ephedra Herb Powder Epitonin or any derivative thereof Ethylenediaminetetraacetic Acid 
(EDTA) Fialuridine 
2,3,8 – Tetrachlorodibenzo-p-
dioxin (2,3,7,8 – TCDD) 
Halogenated 8 & Hydroxy 
Quinoline Hormone Replacement Therapy of 
Thimerosal or Thiomersal 
Animal Origin Hydroquinone 
Isotretinoin or Accutane 
Tobacco or any tobacco 
products (or ingredients thereof) 
Latex &/or latex protein &/or latex 
derivatives &/or latex substances howsoever the latex, latex protein, latex derivatives or latex substances are named, identified, described or classified. Leflunomide 
Trovafloxacin or Alatrofloxacin 
Urea Formaldehyde or any 
products containing Formaldehyde 
      
 
If you have answered YES to any of the products above please provide full details as follows: 
a) 
Are products supplied on a Named Patient 
Basis only or in accordance with Specials Licence granted? If YES please provide details of licence held If NO please provide the following: 
Product details enclosing Data Safety 
Sheets where possible 
If manufactured, to whose 
formula/specification. 
If marketed only, are rights of recourse 
maintained against manufacturers/suppliers? 
How long have you marketed or 
manufactured the products. 
Estimated annual turnover per specific 
If exports involved details of territories to be supplied and estimated turnover. 
PREMISES 
a) Have all Manufacturing location by 
inspected by TGA/FDA or other regulatory body? If YES what was date of lost inspection 
b) Have you ever had a manufacturing licence 
withdrawn? If YES please give details including remedies 
      
Has any Insurer ever:- 
Declined your proposal for Public &/or 
Products Liability insurance 
refused your renewal for Public &/or 
Products Liability insurance 
Terminated your Insurance for Public 
&/or Products Liability. 
Have any incidents occurred during the last 
five years resulting, or alleged to have resulted in death, injury or disease to third parties or damage to their property? 
If YES, please give full details below: 
Brief Details of Incident whether or not an 
Paid Amount 
Insurers 
insurance claim has been made 
Outstanding 
If possible please supply confirmed claims experience from previous / current Insurers 
Are you aware of any circumstances that 
might give rise to a claim? 
If YES, please give details 
d) Please state if your existing cover for 
Products Liability is on a "Claims made" basis or a "Losses occurring" basis. 
If on a "Claim made" basis please state 
retroactive date currently applied to your policy 
e) Who are your current Insurer(s)? If 
currently uninsured please state. 
f) What is the renewal date of your current 
Insurance policy covering Public and Products Liability? 

      
g) Please state Limit(s) of Indemnity for which 
a quotation is required or local currency equivalent 
I/We declare that to the best of my/our knowledge and belief the above statements are true and 
complete and will form part of the contract between me/us and the Underwriters. 
 
Name and position of person completing this 
Edge Underwriting Pty Ltd 
Level 3, 31 Ventnor Avenue 
West Perth WA 6005 
ABN 50 150 700 468 
AFS licence No. 407682 
Source: http://edgeunderwriting.com.au/insurance/2016/02/20120101-CGL-Prop-Pharm.pdf
   Lei aden zum ThemaHIV / Aids für MitarbeiterInnen im Gesundheits- und Sozialbereich Aidshilfe Salzburg, Linzer Bundesstr. 10, 5020 Salzburg Tel.: 0662 88 14 88, salzburg@ aidshilfen.at ,www.aidshilfe-salzburg.at Für das Personal medizinischer Einrichtungen besteht eine mögliche berufl iche Ge-fährdung bei Kontakt mit Blut und bluthal gen Sekreten, insbesondere bei perkutaner Exposi on, z.B. bei Verletzung mit Kanülen oder Skalpellen, die bei HIV-infi zierten Pa-
  
   seems always to be the woman. This probably relates to the X-chromosomal localization of DCX. 1. des Portes V, Pinard JM, Billuart P, et al. A novel CNS gene required Our study has important implications for genetic for neuronal migration and involved in X-linked subcortical laminar counseling of families with SBH/XLIS patients. Ow- heterotopia and lissencephaly syndrome. Cell 1998;92:51– 61.